bluebird bio Inc
NASDAQ:BLUE
Intrinsic Value
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. [ Read More ]
The intrinsic value of one BLUE stock under the Base Case scenario is 10.59 USD. Compared to the current market price of 1.28 USD, bluebird bio Inc is Undervalued by 88%.
Valuation Backtest
bluebird bio Inc
Run backtest to discover the historical profit from buying and selling BLUE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of bluebird bio Inc's business.
What risks and challenges
does bluebird bio Inc face in the near future?
Summarize the latest earnings report
of bluebird bio Inc.
Provide P/E
for bluebird bio Inc and its competitors.
Balance Sheet Decomposition
bluebird bio Inc
Current Assets | 247.1m |
Cash & Short-Term Investments | 174.2m |
Receivables | 23m |
Other Current Assets | 49.9m |
Non-Current Assets | 366.5m |
PP&E | 304.7m |
Intangibles | 11m |
Other Non-Current Assets | 50.8m |
Current Liabilities | 159m |
Accounts Payable | 19.9m |
Accrued Liabilities | 121.5m |
Other Current Liabilities | 17.6m |
Non-Current Liabilities | 232.1m |
Other Non-Current Liabilities | 232.1m |
Earnings Waterfall
bluebird bio Inc
Revenue
|
21.8m
USD
|
Cost of Revenue
|
-24.1m
USD
|
Gross Profit
|
-2.3m
USD
|
Operating Expenses
|
-328.8m
USD
|
Operating Income
|
-331.1m
USD
|
Other Expenses
|
239.9m
USD
|
Net Income
|
-91.2m
USD
|
Free Cash Flow Analysis
bluebird bio Inc
What is Free Cash Flow?
BLUE Profitability Score
Profitability Due Diligence
bluebird bio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
bluebird bio Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
BLUE Solvency Score
Solvency Due Diligence
bluebird bio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
bluebird bio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLUE Price Targets Summary
bluebird bio Inc
According to Wall Street analysts, the average 1-year price target for BLUE is 5.44 USD with a low forecast of 1.03 USD and a high forecast of 13.65 USD.
Ownership
BLUE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BLUE Price
bluebird bio Inc
Average Annual Return | -47.82% |
Standard Deviation of Annual Returns | 11.9% |
Max Drawdown | -99% |
Market Capitalization | 246.7m USD |
Shares Outstanding | 192 742 000 |
Percentage of Shares Shorted | 18.91% |
BLUE News
Last Important Events
bluebird bio Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
bluebird bio Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s programs in genetic diseases include betibeglogene autotemcel (beti-cel) as a treatment for transfusion-dependent B-thalassemia (TDT); LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company develops LentiGlobin gene therapy for patients with SCD, a hereditary blood disorder resulting from a mutation in the b-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. The beti-cel is marketed as ZYNTEGLO for the treatment of adult and adolescent patients with TDT in the European Union. Its product candidate also include SKYSONA for the treatment of patients with CALD in the European Union, Iceland, Liechtenstein and Norway.
Contact
IPO
Employees
Officers
The intrinsic value of one BLUE stock under the Base Case scenario is 10.59 USD.
Compared to the current market price of 1.28 USD, bluebird bio Inc is Undervalued by 88%.